MTHFR and MTRR Genetic Polymorphism of Methotrexate Therapy Outcomes in Early Rheumatoid Arthritis

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2023 May 9

PMID 37159804

Authors

Qian Zhang

Pan Fu

Zhanglei Cao

Hua Huang

Qinwen Wen

Kaizhe Wang

Tong Kong

Xiudi Wu

Jianping Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Methotrexate (MTX) is used as an anchor drug for the treatment of rheumatoid arthritis (RA) and there may be differences in drug action between genotypes. The purpose of this study was to investigate the relationship between clinical efficacy response and disease activity of MTX monotherapy with methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms.

Patients And Methods: In the study, a population of 32 patients in East China with early RA fulfilling the diagnostic standards of the American College of Rheumatology (ACR) were enrolled, all of them received MTX monotherapy. Genotyping of patients MTHFR C677T and A1298C, MTRR A66G using tetra-primer ARMS-PCR method and sanger sequencing to verify its accuracy.

Results: The distribution of three polymorphic genotypes that were studied is in accordance with the Hardy-Weinberg genetic equilibrium. The patient pathology variables smoke (OR = 0.088, P = 0.037), drink alcohol (OR = 0.039, P = 0.016) and males (OR = 0.088, P = 0.037) were significantly associated with non-response to MTX. Genotype, allele distribution and genetic statistical models were not found to be related to MTX treatment response and disease activity in both the response groups and non-response groups.

Conclusion: Our findings suggest that the MTHFR C677T, MTHFR A1298C and MTRR A66G polymorphisms may not predict MTX clinical treatment response and disease activity in patients with early RA. The study revealed that smoke, alcohol, and males were possible influential factors for MTX non-response.

References

Torres R, Pimentel Santos F, Branco J . Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis. ARP Rheumatol. 2022; 1(3):225-229. View

Bansard C, Lequerre T, Daveau M, Boyer O, Tron F, Salier J . Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford). 2009; 48(9):1021-8. DOI: 10.1093/rheumatology/kep112. View

Du B, Tian H, Tian D, Zhang C, Wang W, Wang L . Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia. Br J Nutr. 2018; 119(8):887-895. DOI: 10.1017/S0007114518000508. View

Kato T, Hamada A, Mori S, Saito H . Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2011; 27(2):192-9. DOI: 10.2133/dmpk.dmpk-11-rg-066. View

Lv S, Fan H, Li J, Yang H, Huang J, Shu X . Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population. Front Pharmacol. 2018; 9:1390. PMC: 6279856. DOI: 10.3389/fphar.2018.01390. View

Fransen J, van Riel P . The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009; 35(4):745-57, vii-viii. DOI: 10.1016/j.rdc.2009.10.001. View

Weinblatt M . Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013; 124:16-25. PMC: 3715949. View

Boughrara W, Benzaoui A, Aberkane M, Moghtit F, Dorgham S, Lardjam-Hetraf A . No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population. Inflamm Res. 2017; 66(6):505-513. DOI: 10.1007/s00011-017-1034-6. View

Kolan S, Li G, Grimolizzi F, Sexton J, Goll G, Kvien T . Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. Front Pharmacol. 2022; 13:1075603. PMC: 9714492. DOI: 10.3389/fphar.2022.1075603. View

10.

Dervieux T, Greenstein N, Kremer J . Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006; 54(10):3095-103. DOI: 10.1002/art.22129. View

11.

Hekmatdoost A, Vahid F, Yari Z, Sadeghi M, Eini-Zinab H, Lakpour N . Methyltetrahydrofolate vs Folic Acid Supplementation in Idiopathic Recurrent Miscarriage with Respect to Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms: A Randomized Controlled Trial. PLoS One. 2015; 10(12):e0143569. PMC: 4668025. DOI: 10.1371/journal.pone.0143569. View

12.

Siddiqui A, Totonchian A, Jabar Ali J, Ahmad I, Kumar J, Shiwlani S . Risk Factors Associated With Non-Respondence to Methotrexate in Rheumatoid Arthritis Patients. Cureus. 2021; 13(9):e18112. PMC: 8527277. DOI: 10.7759/cureus.18112. View

13.

Lopez-Rodriguez R, Ferreiro-Iglesias A, Lima A, Bernardes M, Pawlik A, Paradowska-Gorycka A . Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018; 8(1):7342. PMC: 5943457. DOI: 10.1038/s41598-018-25634-y. View

14.

Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V . Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int. 2014; 2014:368681. PMC: 4055378. DOI: 10.1155/2014/368681. View

15.

Li X, Jiang J, Xu M, Xu M, Yang Y, Lu W . Individualized supplementation of folic acid according to polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR) reduced pregnant complications. Gynecol Obstet Invest. 2015; 79(2):107-12. DOI: 10.1159/000367656. View

16.

Jansen G, de Rotte M, de Jonge R . Smoking and Methotrexate Inefficacy in Rheumatoid Arthritis: What About Underlying Molecular Mechanisms?. J Rheumatol. 2021; 48(10):1495-1497. DOI: 10.3899/jrheum.210217. View

17.

Soukup T, Dosedel M, Pavek P, Nekvindova J, Barvik I, Bubancova I . The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Rheumatol Int. 2015; 35(7):1149-61. DOI: 10.1007/s00296-015-3219-z. View

18.

Swierkot J, Slezak R . [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 2)]. Postepy Hig Med Dosw (Online). 2011; 65:207-15. DOI: 10.5604/17322693.936691. View

19.

Muralidharan N, Gulati R, Misra D, Negi V . Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients. Clin Exp Med. 2017; 18(1):101-107. DOI: 10.1007/s10238-017-0469-y. View

20.

Murto T, Kallak T, Hoas A, Altmae S, Salumets A, Nilsson T . Folic acid supplementation and methylenetetrahydrofolate reductase (MTHFR) gene variations in relation to in vitro fertilization pregnancy outcome. Acta Obstet Gynecol Scand. 2014; 94(1):65-71. DOI: 10.1111/aogs.12522. View